STOCK TITAN

Hinge Health (HNGE) Financials

HNGE NYSE
Trailing 12 months to September 30, 2026
Revenue $800.8M YoY not available
Net Income $168.3M n/m YoY
EPS (Diluted) -$7.77 FY2025 annual
Free Cash Flow $322.0M +121.4% YoY
Market Cap $9.3B as of Nov 17, 2026
Price / Sales 11.6x on $800.8M revenue, trailing 12 months to September 30, 2026
Price / Earnings 55.2x on $168.3M net income, trailing 12 months to September 30, 2026
Price / Book 31.1x on $299.4M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HNGE SEC filings page.

Hinge Health, Inc. (HNGE) reported $800.8M in revenue over the twelve months to Sep 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HNGE FY2025

Revenue is scaling, but 2025 spending overwhelmed gross profit even as cash generation stayed positive and equity turned positive.

The cash-generation gap is unusually wide: operating cash flow was $171M, nearly matching FCF of $171M. The business nevertheless reported a net loss of $528M, so FY2025 cash movement did not track accounting profitability; cash flow needs to be read alongside the income statement.

Gross margin reached 79.7% in FY2025, up 2.8 pp, but operating margin fell 84.8 pp. Expense intensity overwhelmed gross economics: SG&A and R&D totaled $1.01B, more than twice gross profit of $468M.

Equity moved from -$435M in FY2024 to $179M in FY2025, indicating a major change in the balance-sheet structure. The short-term cushion narrowed: current ratio fell from 2.3x to 1.5x, so improved equity did not translate into stronger near-term coverage.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 81 / 100
Financial Health Score 81/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Hinge Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
87

Hinge Health, Inc. held $477.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $171.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Hinge Health, Inc. scores 87/100 among other emerging companies.

Dilution
100

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Hinge Health, Inc. scores 100/100 on it among other emerging companies.

R&D Intensity
65

Hinge Health, Inc. spent $368.1M on research and development in fiscal year 2025, which was 32.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Hinge Health, Inc. scores 65/100 among other emerging companies.

Revenue Progress
75

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Hinge Health, Inc. scores 75/100 on it among other emerging companies.

Burn Trend
99

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Hinge Health, Inc. scores 99/100 on it among other emerging companies.

Balance Sheet
57

Hinge Health, Inc.'s cash, cash equivalents and investments came to $477.0M at the end of fiscal year 2025, against $566.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Hinge Health, Inc. scores 57/100 among other emerging companies.

Altman Z-Score Safe
6.52

Hinge Health, Inc. scores 6.52, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $9.3B against total liabilities of $566.1M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
4/7

Hinge Health, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Mixed
N/A

Hinge Health, Inc. reported a net loss of $528.3M while generating $171.4M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$235.0M
YoY+52.4%
QoQ+10.4%

Hinge Health, Inc. generated $235.0M in revenue in Q3 2026. This represents an increase of 52.4% from the same quarter a year earlier. Against the prior quarter it is up 10.4%.

EBITDA
$51.7M
YoYn/m
QoQ+26.7%

Hinge Health, Inc.'s EBITDA was $51.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 26.7%.

Net Income
$57.4M
YoYn/m
QoQ+31.4%

Hinge Health, Inc. reported $57.4M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 31.4%.

EPS (Diluted)
$0.66
YoYn/m
QoQ+26.9%

Hinge Health, Inc. earned $0.66 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 26.9%.

Cash & Balance Sheet

Free Cash Flow
$114.2M
YoY+38.7%
QoQ+12.8%

Hinge Health, Inc. generated $114.2M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 38.7% from the same quarter a year earlier. Against the prior quarter it is up 12.8%.

Cash & Debt
$211.6M
YoY-19.1%
QoQ-26.1%

Hinge Health, Inc. held $211.6M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
Diluted avg 87M

Hinge Health, Inc. had a weighted average of 87M diluted shares in Q3 2026; the shares outstanding count is not reported for that period.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
87.0%
YoY+5.1pp
QoQ+0.5pp

Hinge Health, Inc.'s gross margin was 87.0% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 5.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.

Operating Margin
21.4%
YoY+25.4pp
QoQ+2.4pp

Hinge Health, Inc.'s operating margin was 21.4% in Q3 2026, reflecting core business profitability. This is up 25.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.4 percentage points.

Net Margin
24.4%
YoY+25.6pp
QoQ+3.9pp

Hinge Health, Inc.'s net profit margin was 24.4% in Q3 2026, showing the share of revenue converted to profit. This is up 25.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.9 percentage points.

Return on Equity
19.2%
YoY+20.1pp
QoQ+6.5pp

Hinge Health, Inc.'s quarterly ROE was 19.2% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 20.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.5 percentage points.

Capital Allocation

R&D Spending
$37.5M
YoY+17.4%
QoQ+10.0%

Hinge Health, Inc. invested $37.5M in research and development in Q3 2026. This represents an increase of 17.4% from the same quarter a year earlier. Against the prior quarter it is up 10.0%.

Share Buybacks
$25.9M
YoYn/m
QoQ-2.4%

Hinge Health, Inc. spent $25.9M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 2.4%.

Capital Expenditures
$376K
YoY+623.1%
QoQ+205.7%

Hinge Health, Inc. invested $376K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 623.1% from the same quarter a year earlier. Against the prior quarter it is up 205.7%.

HNGE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HNGE quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$235.0M+52.4%$212.8M+53.0%$182.3M+47.2%$170.7M$154.2M+53.3%$139.1M+54.9%$123.8MN/A
Cost of Revenue$30.6M+9.4%$28.9M-30.2%$28.1M+19.0%$26.7M$28.0M+31.2%$41.3M+78.1%$23.6MN/A
Gross Profit$204.3M+61.9%$183.9M+88.2%$154.2M+53.9%$144.0M$126.2M+59.2%$97.8M+46.8%$100.2MN/A
R&D Expenses$37.5M+17.4%$34.1M-87.8%$30.3M+29.1%$32.8M$31.9M+34.2%$280.0M+1023.4%$23.5MN/A
SG&A Expenses$116.5M+16.1%$109.5M-72.5%$91.8M+44.4%$84.0M$100.4M+69.2%$398.5M+572.5%$63.6MN/A
Operating Income$50.3Mn/m$40.4Mn/m$32.1M+144.1%$27.3M-$6.1Mn/m-$580.7Mn/m$13.1MN/A
EBITDA$51.7Mn/m$40.8Mn/m$33.2M+130.2%$28.5M-$5.6Mn/m-$580.2Mn/m$14.4MN/A
Income Tax-$3.7M-1886.9%$740Kn/m$814K-18.4%$120K$206K-81.4%-$326K-190.3%$998KN/A
Net Income$57.4Mn/m$43.7Mn/m$35.1M+105.0%$32.1M+18.4%-$1.8M-640.8%-$575.7Mn/m$17.1Mn/m$27.1M
EPS (Basic)$0.71n/m$0.55$0.43-94.6%N/A-$0.02-$13.10$7.91$2.01
EPS (Diluted)$0.66n/m$0.52$0.41-68.7%N/A-$0.02-$13.10$1.31$2.01
Diluted Shares (Avg)87M+9.7%83M82M-11.2%N/A79M44M93MN/A

Not reported in any period shown, so not listed: Interest Expense.

HNGE Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HNGE quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$874.1M+13.5%$827.4M+19.3%$728.8M$744.8M+10.6%$769.8M$693.7MN/A$673.3M
Current Assets$567.9M-13.8%$643.4M+7.5%$540.1M$533.9M-8.5%$658.9M$598.4MN/A$583.4M
Cash & Equivalents$211.6M-19.1%$286.2M+20.7%$186.7M-35.3%$208.0M-30.8%$261.3M-2.3%$237.2M+0.2%$288.5M$300.8M
Short-Term Investments$83.1M-62.0%$103.2M-41.4%$129.2Mn/m$155.9M-6.0%$218.7Mn/m$176.1Mn/m$0$165.8M
Inventory$19.2M+38.9%$16.8M+19.9%$14.2M$15.6M+43.8%$13.8M$14.0MN/A$10.9M
Accounts Receivable$148.5M+71.2%$125.4M+26.3%$114.9M$66.1M+55.5%$86.8M$99.3MN/A$42.5M
Long-Term Investments$59.5M+294.9%$84.7Mn/m$89.8Mn/m$113.2Mn/m$15.1Mn/m$0n/m$0$0
Goodwill$113.0M+76.3%$64.1M0.0%$64.1M$64.1M+4.0%$64.1M$64.1MN/A$61.6M
Total Liabilities$574.7M+2.3%$483.1M-7.1%$617.1M$566.1M-48.9%$561.8M$519.9MN/A$1.1B
Current Liabilities$544.7M+52.5%$481.4M+53.3%$414.5M$362.4M+45.4%$357.1M$314.1MN/A$249.3M
Non-Current Liabilities$30.0M-85.4%$1.6M-99.2%$202.6M$203.7M-76.3%$204.7M$205.8MN/A$858.5M
Total Equity$299.4M+44.0%$344.3M+98.1%$111.7Mn/m$178.7Mn/m$208.0Mn/m$173.8Mn/m-$308.3Mn/m-$434.6M
Retained Earnings-$914.8Mn/m-$972.2Mn/m-$1.0B-$1.1Bn/m-$1.1B-$1.1BN/A-$522.7M

Not reported in any period shown, so not listed: Long-Term Debt.

HNGE Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HNGE quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$114.6M+39.1%$101.4M+401.4%$43.1M+774.8%$63.9M+66.7%$82.4M+190.2%$20.2M$4.9M$38.3M
Depreciation & Amortization$1.4M+180.0%$400K-20.0%$1.2M-10.0%$1.2M-10.5%$500K-16.7%$500K-16.7%$1.3M$1.4M
Stock-Based Compensation$19.5M-43.9%$19.1M-96.8%$11.7M+166928.6%N/A$34.8M+30201.7%$591.0M+193031.7%$7KN/A
Capital Expenditures$376K+623.1%$123K-37.6%$83K+62.7%$408K+159.9%$52K-83.5%$197K$51K$157K
Free Cash Flow$114.2M+38.7%$101.3M+405.7%$43.0M+782.2%$63.5M+66.3%$82.3M+193.2%$20.0M$4.9M$38.2M
Investing Cash Flow-$64.2Mn/m$28.6M+611.7%$48.1Mn/m-$37.7Mn/m-$58.8M-2425.2%$4.0M-$21.3M-$3.1M
Financing Cash Flow-$122.3M-23123.7%-$30.5Mn/m-$112.8M-2849.7%-$79.5Mn/m$531Kn/m-$75.6M$4.1M-$2.3M
Share Buybacks$25.9Mn/m$26.5Mn/m$105.0Mn/m$65.0M$0$0$0N/A

Not reported in any period shown, so not listed: Dividends Paid.

HNGE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HNGE quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin87.0%+5.1pp86.4%+16.2pp84.6%+3.6pp84.4%81.8%+3.1pp70.3%-3.9pp81.0%N/A
Operating Margin21.4%+25.4pp19.0%17.6%+7.0pp16.0%-4.0%-0.1pp-417.5%10.6%N/A
Net Margin24.4%+25.6pp20.5%19.3%+5.4pp18.8%-1.2%-1.5pp-413.8%13.8%N/A
Return on Equity19.2%+20.1pp12.7%+344.0pp31.4%18.0%-0.9%-331.3%N/AN/A
Return on Assets6.6%+6.8pp5.3%+88.3pp4.8%4.3%+0.3pp-0.2%-83.0%N/A4.0%
Current Ratio1.04-0.8x1.34-0.6x1.301.47-0.9x1.851.91N/A2.34
Liabilities-to-Equity1.92-0.8x1.40-1.6x5.533.172.702.99N/AN/A
Asset Turnover0.27+0.1x0.26+0.1x0.250.230.200.20N/AN/A
FCF Margin48.6%-4.8pp47.6%+33.2pp23.6%+19.7pp37.2%53.4%+25.5pp14.4%3.9%N/A

Not reported in any period shown, so not listed: Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Hinge Health, Inc. HNGE FY2025 $587.9M -$528.3M -89.9% $9.3B 81/100
HealthEquity, Inc HQY FY2026 $1.3B $215.2M 16.4% $8.4B 70/100
Doximity, Inc. DOCS FY2026 $644.9M $196.1M 30.4% $5.6B 89/100
Waystar Holding Corp. WAY FY2025 $1.1B $112.1M 10.2% $5.3B 60/100
Heartflow, Inc. HTFL FY2025 $176.0M -$116.8M -66.3% $4.1B 60/100
Privia Health Group, Inc. PRVA FY2025 $2.1B $22.9M 1.1% $3.2B 44/100

Frequently Asked Questions

Hinge Health, Inc. (HNGE) reported $587.9M in total revenue for fiscal year 2025. This represents a 50.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Hinge Health, Inc. (HNGE) revenue grew by 50.6% year-over-year, from $390.4M to $587.9M in fiscal year 2025.

Yes, Hinge Health, Inc. (HNGE) reported a net income of $168.3M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $528.3M, with a net profit margin of -89.9%.

Hinge Health, Inc. (HNGE) reported diluted earnings per share of -$7.77 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hinge Health, Inc. (HNGE) had EBITDA of -$541.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Hinge Health, Inc. (HNGE) had a gross margin of 79.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Hinge Health, Inc. (HNGE) had an operating margin of -92.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Hinge Health, Inc. (HNGE) had a net profit margin of -89.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Hinge Health, Inc. (HNGE) has a return on equity of -295.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Hinge Health, Inc. (HNGE) generated $170.7M in free cash flow during fiscal year 2025. This represents a 256.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Hinge Health, Inc. (HNGE) generated $171.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Hinge Health, Inc. (HNGE) had $744.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Hinge Health, Inc. (HNGE) invested $708K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Hinge Health, Inc. (HNGE) invested $368.1M in research and development during fiscal year 2025.

Yes, Hinge Health, Inc. (HNGE) spent $65.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Hinge Health, Inc. (HNGE) had 0 shares outstanding as of fiscal year 2025.

Hinge Health, Inc. (HNGE) had a current ratio of 1.47 as of fiscal year 2025, which is considered adequate.

Hinge Health, Inc. (HNGE) had a liabilities-to-equity ratio of 3.17 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Hinge Health, Inc. (HNGE) had a return on assets of -70.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Hinge Health, Inc. (HNGE) trades at 55.2x earnings, its market capitalization divided by $168.3M net income, trailing 12 months to September 30, 2026. The market capitalization is $9.3B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Hinge Health, Inc. (HNGE) trades at 11.6x sales, its market capitalization divided by $800.8M revenue, trailing 12 months to September 30, 2026. The market capitalization is $9.3B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Hinge Health, Inc. (HNGE) has an Altman Z-Score of 6.52, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Hinge Health, Inc. (HNGE) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Hinge Health, Inc. (HNGE) reported a net loss of $528.3M while generating $171.4M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Hinge Health, Inc. (HNGE) scores 81 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top